C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 28% Dip In Price Shows Sentiment Is Matching Revenues

Simply Wall StJun 1 08:05 ET

Here's What Analysts Are Forecasting For C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its First-Quarter Results

Simply Wall StMay 10 08:09 ET

C4 Therapeutics Updates on Cemsidomide Clinical Trial

TipRanksMay 7 07:30 ET

Express News | C4 Therapeutics' Cash, Cash Equivalents And Marketable Securities Of $234.7M As Of March 31, 2025 Expected To Provide Runway Into 2027

BenzingaMay 7 07:15 ET

C4 Therapeutics Reports Q1 EPS (37c), Consensus (42c)

TipRanksMay 7 07:11 ET

C4 Therapeutics | 10-Q: Q1 2025 Earnings Report

SECMay 7 07:09 ET · Announcements